A main hurdle to killing Epstein-Barr virus (EBV)-infected tumor cells using oncolytic therapy is the presence of a significant fraction of EBV-infected cells that does not support the lytic phase of EBV despite exposure to lytic cycle-promoting agents. We examined our microarray data established as a result, mobile proteomes of separated refractory and lytic cells,… Continue reading A main hurdle to killing Epstein-Barr virus (EBV)-infected tumor cells using